Merus

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MacroGenics

Seagen

Zymeworks Inc

With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.

4 Stocks Battling Breast Cancer

Company to host investor call on Monday, October 28th at 8:00AM ET Company to host investor call on Monday, October 28th at 8:00AM ET

Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

UTRECHT, The Netherlands, Aug.  19, 2019  (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2019 and provided a business update.

Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update

Merus is looking like an interesting pick from a technical perspective.

Moving Average Crossover Alert: Merus

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Merus N.V. (MRUS) Report Negative Q2 Earnings?

As of late, it has definitely been a great time to be an investor in Merus N.V. (MRUS).

Merus N.V. (MRUS) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Merus.

Will Merus Continue to Surge Higher?

Merus is demonstrating strong trading analytics amid the recent market hiccup relating to Dr. Gottlieb's sudden departure.

IBI Research On Merus: Elucidating The Prospects Of An Antibody Innovator

News for Merus Stock (MRUS)